sulfur
vi
base
moieti
especi
sulfonyl
sulfonamid
base
analogu
show
varieti
pharmacolog
properti
deriv
propos
high
degre
structur
divers
establish
use
find
new
therapeut
agent
develop
new
less
toxic
low
cost
highli
activ
sulfonamid
contain
analogu
hot
research
topic
medicin
chemistri
current
fda
approv
sulfur
vi
base
drug
avail
market
wide
use
treat
variou
type
diseas
therapeut
power
comprehens
review
highlight
recent
develop
sulfonyl
sulfonamid
base
compound
huge
rang
therapeut
applic
antimicrobi
antiinflammatori
antivir
anticonvuls
antitubercular
antidiabet
antileishmani
carbon
anhydras
antimalari
anticanc
medicin
agent
believ
review
articl
use
inspir
new
idea
structur
design
develop
less
toxic
power
sulfur
vi
base
drug
numer
deathcaus
diseas
sulfonamid
sulfonyl
function
group
import
motif
medicin
chemistri
sinc
earli
discoveri
sulfonamid
contain
antibacteri
drug
applic
sulfonyl
sulfonamid
function
group
medicin
chemistri
ignor
constitut
import
class
drug
use
extens
agricultur
pharmaceut
agent
featur
vi
contain
speci
strong
electron
withdraw
natur
stabil
hydrolysi
resist
reduct
sulfur
crisp
prefer
twoelectron
process
radic
process
alreadi
made
group
applic
mani
product
field
sulfonamid
synthet
antifol
agent
wide
use
anticip
treat
bacteri
infect
biolog
system
recent
evok
high
favor
biolog
medicin
due
wide
array
biolog
activ
antibacteri
antifung
antiinflammatori
antioxid
antitubercular
antidiabet
hiv
proteas
inhibitor
antiglaucoma
antiobes
antivir
antimalaria
mmp
inhibitor
nonpeptid
vasopressin
receptor
antagonist
translat
initi
inhibitor
etc
date
fda
approv
drug
bear
sulfur
vi
motif
avail
market
celecoxib
meloxicam
piroxicam
sulfasalazin
divers
pharmacolog
activ
vi
organ
molecul
make
first
choic
incorpor
hybrid
approach
present
requir
medicin
access
market
heterocycl
compound
play
essenti
role
life
biochem
process
among
huge
number
novel
sulfonamid
deriv
report
test
vivo
vitro
antitumor
activ
highli
potent
analogu
test
clinic
trial
hope
may
lead
new
altern
anticanc
drug
avoid
side
effect
avail
pharmacolog
agent
sulfur
vi
contain
drug
still
wide
use
circumst
spot
urinari
tract
infect
receiv
renew
interest
treatment
infect
caus
bacteri
resist
antibiot
excel
biolog
profil
hydrolyt
stabil
crystallin
natur
sulfonamid
grab
signific
attent
synthet
chemist
sulfonamid
analogu
trace
number
well
establish
potenti
drug
belong
variou
type
therapeut
agent
repres
sulfonamid
sulfonyl
function
group
contain
fda
approv
drug
list
tabl
search
new
potent
multitarget
sulfonamid
sulfonyl
drug
mani
medicin
chemistri
scholar
focus
sulfonamid
nucleu
import
area
medicin
chemistri
drug
develop
core
substitu
divers
biolog
agent
order
overcom
resist
reduc
advers
effect
continu
effort
made
synthes
novel
multitarget
bioactiv
sulfonamid
analogu
regard
combin
certain
sulfonamid
drug
molecul
use
develop
novel
formul
greater
effect
well
less
toxic
present
comprehens
review
aim
recapitul
recent
biolog
applic
made
toward
discoveri
novel
sulfonyl
sulfonamid
function
group
contain
analogu
potenti
therapeut
agent
critic
aspect
design
structureact
relationship
sar
studi
also
briefli
explain
problem
antibiot
resist
among
pathogen
bacteria
old
antibiot
antibiot
resist
acceler
use
misus
antimicrobi
drug
major
global
challeng
public
health
dramat
increas
human
pathogen
bacteria
observ
past
decad
due
resist
one
antibiot
number
infect
caus
resist
organ
fail
respond
convent
treatment
case
last
resort
antibiot
also
lost
power
search
new
antibiot
sulfonamid
function
group
fundament
motif
medicin
chemistri
sinc
earli
discoveri
sulphonamid
contain
antibacteri
drug
date
number
sulfonyl
sulfonamid
bear
aromat
heterocycl
quinazolinon
oxazol
benzimidazol
thiazol
pyridazin
success
develop
employ
clinic
presenc
sulfadiazin
sulfachlorpyridazin
sulfathiazol
sulfisoxazol
exhibit
excel
antimicrobi
activ
weak
effect
even
loss
resist
power
old
antibiot
new
upcom
bacteri
pathogen
urgent
altern
need
develop
novel
less
toxic
highli
effect
antimicrobi
agent
distinct
structur
fight
emerg
antibioticresist
bacteri
infect
first
part
review
articl
focus
sulfonamid
analogu
core
substitu
antibacteri
agent
drug
develop
regard
combin
sulfonamid
heterocycl
drug
molecul
use
develop
novel
antibiot
drug
sulfonyl
sulfonamid
contain
heterocycl
potenti
antimicrobi
agent
summar
fig
zhou
et
al
design
synthes
novel
seri
benzimidazolederiv
sulfonamid
analogu
evalu
vitro
antimicrobi
activ
differ
microbi
pathogen
compound
fig
show
excel
antibacteri
activ
aureu
mic
valu
mgml
replac
group
group
fig
show
good
antibacteri
activ
b
typhi
mic
valu
mgml
compound
show
eight
fold
higher
activ
mic
mgml
standard
chloromycin
b
typhi
research
group
develop
class
new
type
sulphonamidecontain
azol
analogu
potenti
antimicrobi
agent
compound
fig
show
excel
antibacteri
activ
p
aeruginosa
mic
valu
mg
ml
kambl
et
al
report
pyrazol
deriv
sulfonamid
analogu
good
antibacteri
agent
compound
fig
show
potent
antibacteri
activ
test
bacteri
strain
aureu
typhimurium
mic
valu
mgml
compound
fig
show
excel
antibacteri
activ
differ
bacteri
pathogen
name
b
subtilli
e
coli
mic
valu
mgml
elucid
structur
activ
relationship
sar
compound
presenc
electron
withdraw
br
cf
group
ewg
sulfonyl
attach
phenyl
ring
increas
bacteri
resist
test
aureu
typhimurium
strain
moieti
replac
br
function
group
insert
cl
function
group
compound
found
highli
activ
anoth
bacteri
strain
b
subtilli
e
coli
lipophil
well
natur
posit
substitu
present
benzen
ring
sulfonamid
end
affect
antimicrobi
activ
nasr
et
al
develop
new
type
continu
next
page
sulfonamid
contain
sulfisoxazol
analogu
evalu
antibacteri
activ
compound
fig
show
promis
antibacteri
activ
test
bacteri
strain
compound
fig
show
excel
antibacteri
activ
epidermidi
p
vulgari
k
pneumonia
bacteri
strain
analysi
sar
reveal
presenc
sulfonamid
group
heterocycl
moieti
increas
lipophil
charact
synthes
compound
research
group
padmaja
synthes
heterocycl
contain
sulfonamid
analogu
evalu
vitro
antimicrobi
activ
variou
microbi
pathogen
use
agar
disc
diffus
method
among
synthes
analogu
isoxazol
contain
sulfon
analog
aureu
mm
b
subtili
mm
k
mm
p
vulgari
mm
diamet
fig
found
exhibit
highest
inhibitori
activ
test
bacteri
strain
presenc
ewg
cl
phenyl
ring
sulfonyl
end
sulfon
group
infatu
stronger
antimicrobi
activ
compar
edg
continu
potent
antimicrobi
drug
develop
sulfon
contain
heterocycl
deriv
lavanya
et
al
report
bi
arylsulfonylisoxazol
analogu
potent
antimicrobi
properti
compound
fig
found
highest
antibacteri
activ
b
subtili
zone
inhibit
mm
mgml
elucid
sar
indic
presenc
ewg
cl
phenyl
ring
sulfon
end
show
maximum
antibacteri
activ
b
subtili
strain
anoth
studi
acid
deriv
synthes
screen
dual
bacteri
rnap
rt
inhibitor
elgah
et
al
compound
fig
display
potenc
test
aureu
high
cellular
antiretrovir
activ
probabl
due
presenc
nonbulki
hydrophil
substitu
ureido
side
chain
rt
inhibit
hydrophil
hydrogen
bond
donor
acceptor
substitu
nphenyl
group
also
improv
inhibitori
activ
compar
electronwithdraw
group
ewg
novel
nsulfonaminoethyloxim
deriv
dehydroabiet
acid
develop
zhang
et
al
test
antibacteri
activ
variou
bacteri
pathogen
among
compound
fig
exhibit
superior
activ
test
five
multidrugresist
aureu
mic
valu
mgml
metacf
phenyl
deriv
show
highest
activ
mic
mgml
aureu
newman
elucid
sar
demonstr
introduc
electron
withdraw
trifluoromethyl
group
cf
meta
posit
phenyl
ring
benefici
increas
antibacteri
activ
select
compar
substitu
chloro
bromo
fluoro
methyl
methoxi
group
interestingli
ortho
substitut
cf
deriv
exhibit
vitro
activ
gramposit
bacteri
strain
mgml
tertbutyl
methoxi
function
group
contain
analogu
show
decreas
antibacteri
activ
addit
substitut
posit
appear
slight
influenc
antibacteri
activ
electron
withdraw
function
group
substitut
deriv
nimbart
cowork
develop
novel
sulfonamid
link
piperidin
pyrazol
analogu
evalu
inhibit
solubl
epoxid
hydrolysi
compound
fig
show
highest
inhibitori
activ
test
bacteri
strain
ic
valu
mm
mm
respect
zengin
cowork
found
new
class
sulfanilamid
potent
antimicrobi
agent
test
bacteri
fungal
strain
compound
fig
found
highest
antimicrobi
activ
b
cereu
mic
valu
mm
e
fecali
mic
valu
mm
sar
studi
reveal
lipophil
analogu
play
crucial
role
produc
antimicrobi
activ
dimethyl
substitut
compound
high
antimicrobi
activ
low
lipophil
charact
seri
sulfonamid
contain
benzothiazol
hybrid
evalu
vitro
antimicrobi
properti
microbi
pathogen
compound
fig
found
higher
antimicrobi
activ
compar
refer
sulfamethoxazoletrimethoprim
mixtur
sar
studi
reveal
presenc
sulfonamid
amino
group
nh
nitro
group
para
posit
phenyl
ring
show
excel
antimicrobi
properti
replac
amino
group
nitro
group
led
decreas
antibacteri
activ
continu
studi
sulphonamid
contain
benzothiazol
analogu
power
antimicrobi
properti
new
class
sulphonamid
contain
benzothiazol
hybrid
synthes
screen
antimicrobi
activ
patel
et
al
presenc
sulfonamid
group
para
posit
phenyl
group
highli
increas
antibacteri
properti
test
bacteri
pathogen
furthermor
presenc
ewg
cl
group
phenyl
ring
also
contribut
increas
antibacteri
activ
diabet
one
sever
diseas
rise
world
accord
estim
data
obtain
around
million
peopl
suffer
diabet
world
may
increas
million
chang
blood
glucos
due
insulin
resist
observ
characterist
diabet
case
give
rais
sever
problem
like
high
blood
pressur
heart
problem
kidney
failur
stroke
blind
therefor
highli
demand
develop
addit
electron
steric
requir
arylsulfonamidothiazol
antidiabet
effect
fig
show
repres
sulfonyl
sulfonamid
potent
antidiabet
agent
navarretev
azquez
cowork
design
develop
naphthalen
contain
sulfonamid
potent
antidiabet
agent
dehydrogenas
among
compound
fig
show
promis
antidiabet
activ
dehydrogenas
inhibit
mm
respect
better
standard
drug
inhibit
sar
studi
suggest
piperidin
pyrrolidin
core
attach
amid
group
activ
compound
test
hybrid
novel
class
thiazolidinedion
base
sulfonamid
hybrid
evalu
antidiabet
activ
peroxisom
prolifer
activ
receptor
pparg
naim
et
al
among
compound
fig
found
excel
pparg
inhibitor
fold
increas
gene
express
dock
studi
compound
display
good
interact
amino
acid
tyr
ser
hie
tyr
arg
met
leu
fig
observ
indic
presenc
hydrophob
moieti
surround
hydrophob
amino
acid
believ
hydrophob
interact
enhanc
ligand
receptor
complex
well
bind
affin
ligand
toward
pparg
rathish
et
al
report
synthesi
antidiabet
activ
sulfonamid
base
pyridazinon
deriv
compound
fig
show
excel
antidiabet
agent
reduct
rise
blood
glucos
level
sar
may
summar
introduct
electron
withdraw
cl
para
posit
phenyl
group
caus
slightli
reduct
activ
hand
presenc
electron
releas
function
group
methoxi
methyl
function
group
phenyl
ring
slightli
caus
reduct
activ
moreov
compound
contain
less
bulki
side
chain
found
favour
increas
antidiabet
activ
effect
vivo
antidiabet
activ
noninsulin
depend
diabet
mellitu
rat
sulfonamid
end
enhanc
antidiabet
properti
recent
improv
drug
resist
potent
antidiabet
drug
emerg
key
role
insulin
signal
target
type
du
cowork
report
novel
ptpib
inhibitor
seri
ureodosulfonamid
base
analogu
among
compound
fig
show
superior
inhibitor
ic
valu
nm
nm
respect
sar
suggest
compound
group
b
ring
identifi
possess
fold
potent
inhibitori
activ
enzym
compound
presenc
conh
group
ring
b
display
high
potent
activ
seri
piperazinesulfonamid
analogu
studi
vitro
aamylas
inhibit
activ
nawaz
et
al
com
stronger
cryptochrom
modul
ec
mm
sar
suggest
presenc
sulfonamid
function
group
improv
lipophil
effici
potent
analog
recent
deka
cowork
prepar
new
seri
thiazolidinedion
hybrid
screen
potent
peroxisom
proliferatoractiv
receptor
g
pparg
among
synthes
analogu
compound
fig
show
maximum
pparg
bind
affin
max
respect
sar
reveal
introduct
divers
aryl
sulfonamid
polar
head
group
tail
part
highli
influenc
pparg
activ
addit
presenc
electron
withdraw
cl
ecf
group
phenyl
ring
sulfonamid
linker
also
play
major
role
increas
activ
presenc
electron
releas
oh
eoch
group
decreas
activ
brune
cowork
design
synthes
class
novel
phenyl
benzenesulfonamid
analogu
potent
ppargtarget
antidiabet
agent
compound
fig
show
potent
activ
pparg
inhibitor
ec
valu
nm
sar
reveal
presenc
ewg
f
br
phenyl
ring
increas
activ
sulfonamid
moieti
bromin
atom
para
posit
aromat
benzen
ring
contribut
potent
activ
pparg
inhibitor
gao
cowork
synthes
novel
seri
deriv
test
vitro
inhibitori
activ
sever
dpp
enzym
compound
fig
found
highli
potent
enzym
ic
valu
nm
compar
standard
drug
alogliptin
sar
suggest
compound
contain
ewg
superior
inhibitori
activ
compar
edg
substitu
furthermor
presenc
addit
aromat
influenc
activ
moreov
molecular
dock
result
indic
ligand
effici
dock
activ
site
catalyt
triad
ser
asp
encompass
pocket
cdocker
interact
energi
last
iqbal
cowork
develop
hybrid
potent
hypoglycem
agent
compound
fig
found
potent
inhibitori
activ
ic
valu
mm
vivo
hypoglycaem
activ
compound
exhibit
reduct
blood
glucos
potent
standard
drug
glibenclamid
reduct
sar
suggest
presenc
ewg
cl
phenyl
ring
highli
influenc
activ
replac
halogen
atom
methyl
methoxi
group
led
reduc
activ
attribut
lower
lipophil
substitu
compar
chlorin
atom
lesser
interact
activ
site
aldos
reductas
activ
realli
affect
group
replac
para
substitut
phenyl
ring
howev
group
found
detriment
activ
larg
size
group
might
respons
neg
effect
inflamm
localis
physic
condit
caus
swell
red
heat
pain
mediat
releas
proinflammatori
mediat
like
bradykinin
cytosin
increas
prostaglandin
synthesi
rate
nonsteroid
antiinflammatori
drug
nsaid
exist
two
isomer
form
constitut
form
induc
form
inhibit
cyclooxygenas
cox
therebi
inhibit
biosynthesi
prostaglandin
pg
role
enzym
maintain
gastric
integr
kidney
function
wherea
involv
inflamm
pain
sulfonamid
moieti
exist
one
ubiquit
pharmacophor
function
group
medicin
chemistri
sulfonamid
group
show
divers
pharmacolog
activ
organ
molecul
henc
becom
prioriti
choos
function
group
incorpor
optim
hybrid
approach
report
earlier
number
sulfonyl
sulphonamid
function
group
contain
heterocycl
compound
utilis
demonstr
potenti
antiinflammatori
activ
moreov
among
highli
market
inhibitor
compris
sulphonamid
moieti
celecoxib
fig
major
determin
select
vivo
efficaci
nimesulid
fig
exampl
small
molecul
nsaid
sold
market
today
sulfonamid
function
potenti
antiinflammatori
analogu
show
fig
class
novel
sulfonamid
potent
antiinflammatori
agent
design
synthes
bear
pyrazolyl
deriv
bekhit
et
al
parachlorophenyl
substitut
compound
fig
emerg
potent
antiinflammatori
agent
protect
exceed
indomethacin
chowdhuri
cowork
report
famili
pyrazol
bear
sulfonamid
analogu
evalu
vitro
antiinflammatori
activ
compound
fig
display
attract
antiinflammatori
activ
compar
standard
antiinflammatori
drug
celecoxib
aspirin
sar
studi
reveal
presenc
ring
significantli
increas
bioisoster
effect
activ
analogu
next
research
group
eldin
et
al
develop
sulfonamid
base
hybrid
potent
antiinflammatori
activ
compound
fig
found
signific
candid
ulcerogen
effect
minim
effect
renal
function
novel
pyrazol
base
sulfonamid
deriv
prepar
cowork
screen
vitro
antiinflammatori
activ
among
compound
fig
show
promis
antiinflammatori
activ
ic
mmolkg
fig
show
excel
antiinflammatori
activ
inhibit
promis
analges
activ
sar
suggest
compound
contain
pharmacophor
exhibit
higher
activ
function
substitut
analogu
except
benzenesulfonamid
azomethin
effect
natur
substitu
pyrazol
nucleu
also
play
major
role
enhanc
antiinflammatori
activ
moham
nissan
report
novel
pyrazol
bear
sulphonamidehydrazon
deriv
potent
antiinflammatori
agent
compound
fig
found
better
antiinflammatori
agent
standard
antiinflammatori
drug
diclofenac
indomethacin
addit
molecular
dock
studi
reveal
compound
interact
tyr
ser
hassan
et
al
synthes
seri
benzofuran
bear
celecoxibsulfonamid
develop
novel
antiinflammatori
agent
among
compound
fig
expos
highest
antiinflammatori
activ
antiinflammatori
data
reveal
essenti
role
compound
bear
pyridin
moieti
enhanc
antiinflammatori
effici
anim
model
ahm
cowork
synthes
new
class
curcumincontain
sulfonamid
analogu
investig
activ
antiinflammatori
compound
fig
identifi
success
antiinflammatori
agent
inhibit
induc
edema
compar
standard
drug
indomethacin
inhibit
kumar
et
al
report
eighteen
pyrazolylpyrazolin
bear
benzenesulfonamid
potent
antiinflammatori
agent
among
compound
fig
show
excel
antiinflammatori
effect
compound
contain
sulfonamid
base
heterocycl
highlight
search
new
antiinflammatori
agent
malaria
parasit
infect
spread
worldwid
mostli
affect
caus
seriou
problem
tropic
subtrop
part
asia
central
south
america
africa
also
million
peopl
affect
part
middl
east
parasit
speci
call
plasmodium
carri
femal
anophel
mosquito
caus
diseas
enter
bloodstream
human
infect
mosquito
treatment
manag
diseas
unreason
high
medic
also
due
low
product
difficulti
control
malaria
lie
grow
resist
malaria
parasit
antimalari
drug
use
henc
strong
need
treat
drugresist
diseas
develop
better
perform
drug
continu
effort
includ
explor
potenti
bioactiv
natur
product
deriv
compound
requir
biolog
activ
antimalari
agent
contain
sulphonamid
group
sulfonamid
group
present
number
potenti
antimalari
analogu
show
result
studi
indic
alkyl
chain
length
critic
antimalari
activ
also
presenc
isopropyl
group
phenyl
ring
sulfonamid
end
highli
enhanc
antimalari
activ
recent
oliveira
cowork
report
potent
sulfonamid
contain
chaclcon
hybrid
evalu
vitro
antimalari
activ
p
falciparum
compound
ic
mm
fig
found
best
antimalari
agent
good
select
index
mutha
cowork
report
class
new
potent
hydroxyethypiperazin
bear
benzenesulfonyl
hybrid
antimalari
agent
synthes
compound
test
vitro
antimalari
activ
p
falciparum
clone
among
compound
ic
mm
fig
display
superior
antimalari
activ
ic
valu
mm
p
falciparum
clone
recent
combin
indoleamid
sulfonyl
report
activ
antimalari
agent
strain
among
compound
fig
respect
sar
reveal
presenc
sulfonyl
analogu
contain
bulki
group
pterbutylphenyl
phenyl
group
show
promis
antiplasmodi
activ
ic
valu
rang
mm
huang
cowork
report
sulphonamid
bear
small
analogu
potent
dual
inhibitor
dhfr
compound
fig
bear
amid
sulphonamid
moieti
found
activ
inhibitor
compound
contain
thiazol
group
amid
moieti
activ
analogu
ic
mm
dhfr
ic
mm
addit
compound
show
reason
vivo
antimalari
activ
compar
standard
drug
chloroquin
diphosph
salt
sar
suggest
presenc
amid
sulphonamid
thiazol
group
play
crucial
role
enhanc
antimalari
activ
caridha
cowork
report
potent
thiophen
benzen
sulfonamid
antimalari
agent
among
bromohydrosulfonylacetamid
fig
found
promis
growth
inhibit
drug
resist
p
falciparum
strain
well
low
toxic
profil
mammalian
cell
line
explor
variat
thiophen
benzen
ring
substitut
may
produc
potent
pfcdk
inhibitor
cunico
cowork
develop
hydroxyethylpiperazin
analogu
evalu
vitro
antimalari
agent
plasmodium
falciparum
clone
compound
found
potent
antimalari
agent
ic
valu
mm
plasmodium
falciparum
clone
almost
activ
standard
lopinavir
sar
reveal
presenc
amin
group
phenyl
ring
influenc
antimalari
activ
addit
presenc
piperazin
moieti
also
essenti
increas
activ
sulfonamid
function
group
bridg
two
bioactiv
analogu
ab
deposit
oxid
stress
dyshomeostasi
biomet
tauprotein
aggreg
consid
pathophysiolog
factor
unfortun
medicin
cure
ad
progress
discov
yet
certain
medicin
approv
prescrib
ad
patient
temporari
relief
part
review
articl
sulfonamid
nucleu
focus
core
substitu
alzheim
agent
develop
drug
sulfonyl
sulfonamid
contain
heterocycl
repres
potenti
alzheim
agent
summar
fig
mutahir
cowork
perform
novel
biphenyl
bissulfonamid
deriv
potent
acetylcholinesteras
ach
butyrylcholinesteras
buch
agent
among
test
compound
compound
fig
found
potent
activ
ach
ic
mm
wherea
fig
exhibit
highest
inhibit
bche
ic
mm
sar
studi
reveal
function
well
benzyl
moieti
nitrogen
play
crucial
role
higher
activ
compound
higher
activ
bear
nhexadecanyl
moieti
nitrogen
similar
trend
case
ach
inhibit
could
attribut
hydrophob
bulki
nhexadecanyl
group
addit
molecular
dock
studi
also
perform
analysi
bind
mode
hydrogen
bond
interact
compound
cholinesteras
enzym
ligand
bind
within
activ
site
ach
limit
hydrophob
interact
anion
subsit
acyl
pocket
well
peripher
anion
site
biphenyl
fragment
engag
specif
pep
chep
interact
arrang
activ
compound
activ
gorg
ach
shown
fig
ligand
bind
within
activ
site
ach
limit
hydrophob
interact
anion
subsit
acyl
pocket
well
peripher
anion
site
pa
biphenyl
fragment
engag
specif
pep
chp
interact
oxygen
atom
sulfonamid
group
might
creat
weak
hbond
hydroxyl
group
union
form
arrang
activ
compound
activ
gorg
ach
shown
fig
similar
result
observ
case
dock
activ
site
bche
bind
test
compound
ach
bche
mainli
provid
due
presenc
hydrophob
interact
sum
assum
bind
test
compound
ach
bche
mainli
provid
due
presenc
hydrophob
interact
howev
obtain
compound
interest
start
point
develop
synthesi
potent
cholinesteras
inhibitor
structur
modif
lead
increas
number
hydrogen
bond
donor
acceptor
augment
strength
specif
bind
enzym
yar
et
al
report
novel
potent
pyridin
analogu
acetylcholinesteras
ach
butyrylcholinesteras
bche
agent
compound
fig
exhibit
potent
activ
test
enzym
ach
ic
mm
bche
ic
mm
overal
compound
bear
phenyl
group
found
activ
test
enzym
hand
ulu
et
al
describ
acridinesulfonamid
hybrid
potent
acetylcholinesteras
inhibitor
treatment
alzheim
diseas
compound
fig
display
superior
activ
ach
ic
mm
later
research
group
ulu
et
al
continu
develop
new
type
alzheim
agent
sulfonamid
bear
tacrin
deriv
synthes
evalu
vitro
acetylcholinesteras
ach
butyrylcholinesteras
buch
activ
compound
fig
found
highest
inhibitori
activ
ach
ic
valu
mm
valu
higher
galantamin
ic
mm
compound
fig
display
strongest
inhibit
buch
ic
valu
mm
elucid
sar
sulfonamid
group
present
para
posit
phenyl
ring
show
good
acetylcholinesteras
activ
ach
presenc
electron
releas
moieti
crucial
higher
activ
ewg
inact
ach
bche
enzym
next
level
investig
author
also
perform
molecular
dock
analysi
potent
compound
detail
explor
bind
pattern
within
activ
site
ach
bche
addit
dock
techniqu
consid
effici
accur
predict
bind
mode
small
molecul
potent
compound
show
detail
explor
bind
pattern
bind
mode
interact
within
activ
site
ach
bche
compound
two
hydrogenbond
interact
peripher
anion
site
residu
upon
bind
ach
fig
addit
dock
complex
bche
show
hydrophob
patch
residu
catalyt
triad
residu
involv
intra
molecular
hydrogen
bond
fig
dock
result
show
capabl
establish
two
hydrogenbond
interact
peripher
anion
site
pa
residu
upon
bind
ach
fig
addit
dock
complex
bche
show
hydrophob
patch
residu
catalyt
triad
residu
involv
intramolecular
hydrogen
bond
fig
elucid
sar
presenc
group
b
ring
chalcon
produc
potent
agent
correspond
deriv
smaller
electron
donat
group
ch
oh
nh
favour
larger
speci
och
ewg
recent
wieckowska
et
al
report
sulfonamid
base
piperidin
hybrid
potent
receptor
antagonist
cholinesteras
inhibitor
among
compound
fig
found
potent
agent
receptor
k
b
nm
ach
buch
hach
ic
nm
hbuch
ic
nm
drug
develop
program
novel
class
multifunct
ligand
evalu
compound
fig
best
deriv
seri
repres
excel
start
point
develop
effect
treatment
ad
dissemin
leishmaniasi
becom
emerg
infecti
diseas
mostli
due
leishmania
braziliensi
l
braziliensi
caus
cutan
mucocutan
leishmaniasi
sever
latin
american
countri
present
parasit
diseas
caus
morbid
mortal
mainli
develop
world
toxic
high
cost
develop
drug
resist
becom
obstacl
prevail
chemotherap
treatment
sodium
stiboglucon
pentostam
meglumin
antimoni
glucantim
two
pentaval
antimoni
sb
v
compound
first
introduc
use
form
leishmaniasi
parenter
administr
therefor
drug
safe
inexpens
easili
avail
need
develop
immedi
lead
compound
also
taken
import
role
futur
treatment
diseas
global
sulfonamid
accord
literatur
shown
versatil
antileishmani
activ
becom
structur
core
leishmanicid
therapi
sulfonamid
group
act
chemic
link
allow
bind
potenti
activ
compon
aromat
heteroaromat
system
along
demonstr
antiparasit
activ
marra
et
al
conduct
studi
aim
prepar
evalu
potent
novel
benzenesulfonamid
hybrid
l
infantum
l
amazonensi
strain
compound
ic
mm
l
infantum
ic
mm
l
amazonensi
ic
mm
l
infantum
ic
mm
l
amazonensi
fig
show
potent
activ
test
l
infantum
l
amazonensi
strain
case
compound
pyrazol
bare
sulfonamid
group
activ
treat
infect
caus
two
leishmania
strain
borg
cowork
report
new
class
pyrazolyl
benzenesulfonamid
hybrid
potent
antileishmani
activ
candid
leishmania
amazonensi
among
compound
ic
valu
mm
fig
found
potent
activ
leishmania
amazonensi
ic
valu
higher
refer
drug
ketoconazol
gonz
alezrosend
et
al
develop
new
seri
naphthalenesulfonamid
analogu
potent
antileishmani
trypanocid
inhibitor
compound
fig
display
potent
inhibit
three
leishmania
speci
entitl
l
infantum
ic
mm
l
amazonensi
ic
mm
cruzi
ic
mm
addit
compound
found
excel
antit
cruzi
candid
clinic
investig
could
use
develop
new
antichagas
drug
group
palop
report
diselenid
contain
sulfonamid
deriv
exhibit
vitro
leishmanicid
activ
leishmania
infantum
intracellular
amastigot
cell
compound
fig
emerg
activ
compound
ic
mm
show
higher
activ
much
less
toxic
cell
refer
drug
edelfosin
sar
studi
clearcut
relationship
found
mutual
result
suggest
sulfonamid
scaffold
could
valuabl
linker
connect
parent
diselenid
parafluoro
phenyl
ring
attach
sulfonamid
end
addit
rodrigu
et
al
design
develop
chalconesulfonamis
analogu
potent
antileishmani
agent
compound
fig
found
best
profil
l
braziliensi
promastigot
ic
valu
mm
moreov
presenc
benzylamino
group
extens
contribut
activ
result
reveal
sulfonamid
base
methoxychalcon
hybrid
lead
compound
design
new
candid
leishmaniasi
treatment
tuberculosi
highli
infecti
chronic
deadli
diseas
caus
bacteria
call
mycobacterium
tuberculosi
mtb
diseas
threat
human
life
affect
lung
primarili
pulmonari
tb
apart
vital
organ
drugresist
tb
drtb
multidrugresist
tb
mdrtb
extens
drugresist
tb
xdrtb
total
drug
resist
tb
tdr
emerg
day
complet
resist
action
present
avail
standard
drug
infect
tb
high
caus
death
around
million
million
clinic
case
globe
report
howev
treatment
tb
drug
isoniazid
inh
ethambutol
rifampicin
rif
pyrazinamid
pza
observ
highli
effect
tb
discoveri
rifampicin
rif
help
obtain
hand
antitb
drug
compound
human
howev
still
number
deriv
explor
stop
activ
bacteria
spread
tb
fig
show
sulfonyl
sulfonamid
contain
heterocycl
potenti
tb
agent
shahul
cowork
report
aminoperidin
benzimidazol
deriv
potent
antitb
agent
mtb
mtb
dna
gyras
compound
fig
exploit
sever
sulfonylhydrazon
also
test
vitro
antitb
agent
mycobacterium
tuberculosisptpb
among
synthes
molecul
compound
ic
mm
ic
mm
ic
mm
ic
mm
fig
show
potent
ptpb
inhibitor
sar
suggest
presenc
ewg
cl
f
phenyl
ring
sulfonamid
end
enhanc
antitb
properti
continu
search
new
type
potent
antitb
agent
reddi
cowork
design
develop
new
sulfonamid
base
indol
hybrid
potent
antitb
agent
compound
fig
found
best
inhibitor
mtbcm
sar
show
indol
contain
rso
nh
c
h
group
posit
sulfonamid
moieti
play
key
role
interact
activ
site
cm
last
novel
hybrid
synthes
screen
vitro
antimycobacteri
activ
mtbh
rv
among
compound
fig
show
excel
antitb
activ
mic
valu
mgml
eight
fold
potent
emb
mic
mgml
pza
mic
mgml
virus
infecti
agent
affect
life
form
respons
caus
variou
danger
diseas
like
human
immunodefici
viru
hiv
hepat
b
c
virus
hbv
hcv
respect
sever
acut
respiratori
syndrom
sar
corona
virus
middl
east
respiratori
syndrom
mer
influenza
season
pandem
viral
haemorrhag
fever
ebola
dengu
chikungunya
etc
diseas
caus
advers
impact
human
health
lead
unexpect
ill
death
troubl
daytoday
normal
life
activ
virus
major
caus
emerg
newer
pandem
eg
influenza
ebola
zika
viru
etc
threaten
public
health
hand
antivir
drug
divers
chemic
class
approv
fda
mainli
manag
hiv
hepat
b
c
herp
influenza
b
virus
still
mani
molecul
variou
stage
clinic
trial
still
press
need
develop
new
drug
act
sever
mechan
combat
viral
resist
virus
constantli
evolv
howev
alway
challeng
medicin
chemist
develop
newer
drug
understand
uniqu
biolog
featur
virus
treat
emerg
viral
diseas
one
way
without
harm
host
cell
fig
show
sulfonyl
sulfonamid
potent
antivir
agent
recent
year
variou
sulphonamid
base
isoxazolidin
hybrid
synthes
evalu
vitro
hiv
fig
found
potent
activ
singl
mutant
ec
mm
respect
potent
refer
drug
azt
result
expect
help
design
thiophenepyrimidinebas
nnrti
potent
activ
hiv
strain
rt
mutat
zhang
et
al
explor
pyridinesulfonamid
potent
hepat
c
hcv
inhibitor
compound
fig
show
outstand
potenc
hcv
replicon
ec
nm
select
index
respect
cellular
gapdh
overal
profil
compound
make
good
aspir
futur
drug
develop
program
sever
thiadiazol
bear
sulfonamid
analogu
also
demonstr
promis
antivir
activ
tobacco
mosaic
viru
half
leaf
method
explor
yang
et
al
compound
fig
show
promis
tmv
inhibit
compar
refer
drug
ningnanmycin
sar
structur
modif
sulfonamid
moieti
wide
impact
antivir
activ
compound
hu
et
al
develop
prepar
new
class
chalconecontain
purin
benzenesulfonamid
hybrid
test
antivir
properti
tmv
cmv
compound
fig
found
possess
outstand
activ
tmv
ec
valu
mgml
better
ribavirin
mgml
sar
analysi
show
introduc
edg
benzenesulfonamid
aromat
ring
low
steric
hindranc
group
promot
antivir
properti
find
indic
chalcon
deriv
worthi
research
develop
templat
new
antivir
agent
compound
fig
found
potent
ki
nm
ic
mm
antivir
activ
oral
bioavail
compound
rang
rat
dog
h
satur
bond
pyron
ring
led
identif
compound
fig
excel
bind
affin
hiv
proteas
ki
valu
nm
excel
antivir
activ
cell
cultur
significantli
less
ed
valu
mm
last
continu
find
new
class
potent
coumarinbenzimidazol
hybrid
potent
antihcv
activ
hwu
et
al
among
compound
ec
mm
ec
mm
fig
display
excel
antivir
activ
chikungunya
viru
chikv
sar
reveal
extens
doubli
conjug
uracilecoumarin
tripli
conjug
uracilecoumarinearen
use
linker
fundament
antichikv
activ
bezouracil
deriv
fig
better
select
index
compar
uracil
fig
thymin
carbon
anhydras
ca
class
metalloenzym
contain
zinc
metal
role
metalloenzym
interconvers
carbon
dioxid
water
bicarbon
proton
maintain
acidbas
balanc
tissu
blood
enzym
multidomain
protein
contain
ca
subdomain
situat
outsid
cell
also
possess
high
co
hydras
catalyt
activ
inhibit
ca
inhibitor
belong
sulphonamid
sulfam
sulfamid
class
compound
today
around
differ
human
ca
known
wide
distribut
differ
tissu
involv
differ
physiolog
process
cell
differenti
prolifer
ph
homeostasi
neurotransmiss
patholog
like
diuret
epilepsi
glaucoma
obes
cancer
sulfonamid
consid
signific
moieti
due
divers
pharmacolog
activ
clinic
use
carbon
anhydras
inhibitor
cai
primarili
diuret
antiglaucoma
agent
heterocycl
ring
aromat
ring
contain
sulfonamid
moieti
zinc
bind
group
tail
approach
afford
cai
possess
high
affin
desir
pharmacolog
properti
alreadi
explor
literatur
recent
famili
sulfonamid
base
heterocycl
hybrid
design
biolog
evalu
potent
carbon
anhydras
activ
hca
hca
nocentini
et
al
compound
fig
found
superior
activ
ic
valu
hca
nm
hca
nm
sar
reveal
presenc
key
function
element
pyrazol
isoxazol
sulfonamid
function
moieti
benefici
enhanc
carbon
anhydras
activ
khalifah
cowork
design
develop
potent
iminothiazolidinonesulfonamid
hybrid
evalu
inhibitori
effect
four
relev
human
h
isoform
carbon
anydras
ca
ec
ii
iv
ix
stoppedflow
co
hydras
assay
compound
fig
show
potent
activ
hcaii
ic
valu
ki
nm
may
due
presenc
ewg
cl
highli
influenc
strongest
inhibitor
hcaii
seri
benzenesulfonamid
link
hybrid
synthes
good
yield
test
vitro
carbon
fig
found
incorpor
amino
hydrazino
ethylamino
dimethylamino
amino
acyl
moieti
show
promis
ca
activ
incorpor
bulki
group
viz
npropyl
nbutyl
diethylaminoethyl
piperazinylethyl
pyridox
amin
phenoxi
show
least
ca
activ
hca
ii
ix
inhibitor
supuran
et
al
report
sulfonamid
link
triazin
moieti
fig
test
carbon
anhydras
transmembran
isoform
ix
xii
xiv
cytosol
isoform
ii
longer
spacer
compound
n
shown
effect
inhibitor
intermedi
spacer
n
turn
effect
shorter
spacer
deriv
n
short
amino
alcohol
deriv
fig
also
shown
effect
bulkier
compound
mert
et
al
report
new
class
contain
pyrazol
hybrid
test
vitro
inhibitori
activ
isoform
human
cytosol
carbon
anhydras
ii
compound
fig
hca
k
mm
compound
fig
hca
ii
k
mm
show
highest
inhibitori
activ
compar
rest
analogu
cannabinoid
receptor
cb
cb
respect
consid
member
g
proteincoupl
receptor
gpcr
superfamili
earli
receptor
abund
neuroregulatori
receptor
present
brain
peripher
organ
adipos
tissu
muscl
liver
regul
feed
appetit
wherea
receptor
mostli
express
immun
system
regul
immun
neurodegener
compound
fig
best
exampl
sulfonamid
group
claim
potent
cannabinoid
receptor
agonist
addit
find
new
sulfonamid
contain
cannabinoid
receptor
drug
scientist
astrazeneca
also
report
potent
sulphonamid
base
drug
fig
act
cb
cb
dual
agonist
administr
pain
recent
watson
cowork
pfizer
report
sulfonylbenzimidazol
hybrid
fig
select
cb
agonist
potenti
analges
agent
devoid
side
effect
associ
cb
agonist
verbist
cowork
identifi
sulfonylbenzimidazol
analogu
fig
potent
cb
receptor
agonist
compound
found
analges
effect
demonstr
pain
model
furthermor
improv
metabol
stabil
solubl
group
optim
compound
led
discoveri
rel
polar
peripher
act
cb
agonist
compound
fig
greig
et
al
design
produc
new
class
indol
sulfonamid
potent
cannabinoid
receptor
compound
fig
display
outstand
potenc
nm
respect
show
good
oral
exposur
cn
penetr
make
highli
versatil
tool
investig
therapeut
potenti
alloster
modul
cannabinoid
system
presenc
sulfonamid
function
prove
extrem
potent
agonist
hcb
receptor
compound
ec
nm
ec
nm
fig
potent
hcb
receptor
agent
result
inspir
develop
vitro
profil
sulfonamid
hcb
receptor
rat
liver
microsom
rlm
chang
et
al
develop
pyrazol
bear
sulfonamid
hybrid
evalu
potent
receptor
antagonist
compound
fig
found
potent
receptor
antagonist
k
valu
nm
nm
ec
nm
compound
current
develop
treat
obes
relat
metabol
syndrom
epilepsi
famili
neurolog
disord
caus
due
disturb
nerv
cell
activ
associ
progress
impair
cognit
function
brain
damag
neurolog
deficit
becom
common
neurolog
condit
affect
million
peopl
fortun
avail
antiepilept
drug
a
allow
epilept
patient
maintain
normal
undisturb
life
satisfi
control
total
relief
seizer
improv
develop
antiepilept
drug
requir
complet
prevent
epilepsi
progress
farag
cowork
develop
set
compound
fig
pharmacophor
hybrid
test
picrotoxin
pic
induc
convuls
mgkg
ip
mice
among
compound
protect
anim
better
refer
drug
phenobarbit
show
mortal
activ
compound
also
show
reason
protect
decreas
mortal
rate
fifti
percent
continu
author
modifi
benzothiazol
pharmacophor
introduc
sulfonamid
group
test
molecul
anticonvuls
activ
use
me
scptz
seizur
test
swiss
albino
mice
compound
fig
found
activ
seizur
test
variant
dose
neurotox
higher
dose
mgkg
similar
standard
drug
carbamazepin
cancer
univers
known
diseas
group
diseas
caus
death
found
exist
world
cancer
meant
bunch
cell
origin
singl
cell
due
uncontrol
growth
rapid
prolifer
properti
problem
drug
unabl
differenti
normal
cancer
cell
type
lead
sever
seriou
side
effect
develop
anticanc
theraupet
agent
becom
challeng
medicin
chemist
continu
effort
carri
area
research
save
million
live
nitin
cowork
design
develop
new
class
benzothiazol
deriv
methyl
sulfonyl
hybrid
potent
anticanc
agent
among
compound
show
superior
anticanc
activ
human
cervic
hela
cell
line
compound
fig
extens
inhibit
cell
growth
gi
valu
found
mm
respect
sar
studi
reveal
presenc
ewg
phenyl
ring
two
sulfonyl
group
analogu
increas
anticanc
activ
addit
search
novel
class
potent
sulfonamid
bear
hybrid
ibrahim
cowork
report
isatinpyrazol
benzenesulfonamid
deriv
potent
ca
inhibitor
compound
fig
show
fig
sulfonyl
sulfonamid
contain
heterocycl
potenti
tb
agent
good
carbon
anhydras
inhibit
cell
line
hca
ix
k
nm
respect
hca
xii
k
nm
respect
sar
studi
suggest
presenc
ewg
phenyl
ring
increas
activ
sulphonamid
play
major
role
enhanc
ca
activ
tiangong
cowork
develop
compound
fig
new
class
styrylsulfonylmethylpyridin
hybrid
anticanc
activ
cell
line
use
mtt
assay
compound
found
best
antitumor
activ
xenograft
colon
cancer
model
gi
valu
mmoll
compound
display
potent
antitumor
efficaci
xenograft
gi
valu
mmoll
sar
studi
reveal
compound
contain
two
sulfoonamid
group
favour
increas
anticanc
activ
presenc
edg
necessari
increas
activ
also
presenc
pyridin
ring
deriv
increas
oral
bioavail
solubl
synthes
compound
r
pingaew
et
al
report
new
class
sulfonyl
contain
thiosemicarbazon
tetrahydroisoquinolin
hybrid
potent
anticanc
agent
synthes
thiosemicarbazon
analogu
show
good
cytotox
potenc
cell
line
ic
valu
mgml
compound
fig
found
best
cytotox
activ
ic
valu
mgml
mgml
respect
sar
display
presenc
edg
ome
sulfonyl
function
increas
cytotox
activ
last
jun
cowork
design
produc
novel
indolin
analogu
good
yield
test
antiprolif
activ
variou
cancer
cell
line
among
compound
fig
show
good
cytotox
ic
valu
rang
mm
mm
respect
four
human
cancer
cell
line
sar
demonstr
presenc
edg
ome
significantli
increas
activ
presenc
oxazol
moieti
also
influenc
antiprolif
activ
romero
cowork
report
new
class
thiazolecontain
tryptamin
hybrid
potent
receptor
agonist
compound
fig
found
good
ki
valu
nm
receptor
compound
display
partial
agonist
properti
camp
function
assay
pki
valu
f
cell
line
vivo
studi
indic
compound
effect
improv
recognit
memori
combin
modul
cholinerg
well
glutamaterg
neurotransmiss
rat
hayat
et
al
found
benzothiazolesulfonamid
hybrid
display
power
receptor
antagonist
hela
cell
line
compound
ic
mm
ic
mm
fig
bear
group
posit
benzothiazol
ring
respect
show
promis
inhibit
receptor
antagonist
hela
cell
line
prio
et
al
patent
variou
deriv
receptor
ligand
numer
substitut
phenyl
well
imidazol
ring
provid
suitabl
ligand
display
excel
affin
receptor
particularli
compound
fig
show
good
ki
valu
nm
respect
last
liu
et
al
explor
number
sulphonamid
base
benzothiazol
hybrid
receptor
agent
produc
hybrid
possess
nanomolar
rang
affin
receptor
among
compound
fig
found
best
potent
receptor
ki
valu
nm
addit
vitro
vivo
studi
compound
fig
may
provid
promis
lead
futur
yang
et
al
design
develop
class
potent
quinolinebas
inhibitor
pharmacokinet
pk
studi
demonstr
compound
fig
realist
drug
exposur
via
po
administr
would
suitabl
vivo
proof
concept
anim
studi
better
understand
physiolog
pathophysiolog
action
enzym
recent
iqbal
cowork
found
sulfonamid
bear
sultam
analogu
potent
alkalin
phosphatas
btnap
biap
inhibitor
among
compound
fig
contain
pnitro
substitu
found
best
activ
inhibitor
ic
valu
mm
examin
highlight
signific
presenc
ewg
para
posit
phenyl
ring
effect
btnap
inhibit
presenc
para
posit
phenyl
ring
found
effici
select
inhibitor
btnap
biap
moreov
homolog
built
model
use
dock
studi
order
ration
probabl
bind
interact
inhibitor
enzym
compound
activ
btnap
inhibitor
sulfonamid
group
found
orient
toward
zn
metal
ion
fig
display
detail
bind
site
interact
activ
btnap
inhibitor
compound
compound
compound
sulfonamid
group
oxygen
atom
pnitro
group
direct
contact
zn
ion
activ
site
sinc
activ
btnap
inhibitor
interact
might
respons
except
inhibitori
activ
observ
compound
presenc
sulfonamid
group
zinc
bind
function
suggest
promin
structur
featur
design
potent
ap
inhibitor
taha
fig
lack
chloro
observ
sevenfold
declin
activ
anoth
compound
fig
lack
chloro
posit
perceiv
nine
time
declin
activ
sar
reveal
decreas
chloro
substitut
trito
disubstitut
decreas
activ
worth
display
synthes
hybrid
biolog
activ
analogu
oxadiazol
ring
sulfon
group
hydrazid
moieti
aryl
ring
cordial
play
role
exhibit
activ
compound
identifi
lead
compound
bglucuronidas
inhibitori
activ
may
use
research
find
power
inhibitor
recent
iqbal
cowork
develop
class
chalconesulfonamid
hybrid
potent
alkalin
phosphatas
inhibitor
among
compound
fig
show
maximum
inhibit
human
rat
ic
valu
mm
respect
sar
studi
suggest
presenc
edg
meta
posit
phenyl
ring
display
greater
inhibit
likewis
presenc
disubstitut
bulki
electron
donat
group
ie
methoxi
group
posit
show
greater
inhibit
fold
higher
standard
compound
sulfam
acid
potent
inhibitor
analyz
activ
pocket
enzym
dock
pose
elabor
presenc
five
strong
hydrogen
bond
variou
amino
acid
residu
compound
also
show
strong
electrostat
interact
two
zinc
ion
within
activ
pocket
show
interact
nitrogen
sulfonamid
moieti
form
metal
acceptor
phenomenon
fda
approv
compound
delavirdin
fig
found
second
nnrti
agent
author
treatment
crystallograph
analysi
confirm
methylsulfonamid
group
indol
ring
essenti
enhanc
activ
moretto
et
al
identifi
novel
pyridothiophen
inhibitor
k
valu
mm
xray
cocryst
structur
compound
fig
show
one
sulphonamid
oxygen
hydrogen
bond
backbon
nitrogen
enter
interact
bridg
water
molecul
fig
interact
could
increas
inhibitor
activ
would
bring
select
tcptp
klopfenstein
cowork
develop
compound
inhibitor
select
tcptp
sulfam
acid
moieti
pick
hydrogen
bond
interact
fig
aim
investig
divers
chemic
space
introduct
imidazopyridin
ring
scaffold
led
discoveri
two
novel
seri
imidazopyridinylthioacetanilid
hybrid
among
compound
ec
mm
mm
respect
fig
identifi
potent
inhibitor
suppress
replic
compound
fig
higher
potenc
compar
refer
drug
dideoxycytidin
later
kim
et
al
design
develop
sulfonamid
contain
hydroxyl
chalcon
fig
potenti
inhibit
transsialidas
enzym
demonstr
ic
valu
mm
continu
search
potenti
sulfonamid
base
chalcon
hybrid
potent
drug
diseas
caus
pathogen
elayach
report
polyphenol
bear
two
polyphenol
moieti
separ
bisarylsulfonamid
fig
moieti
essenti
activ
substitut
benzyl
methylen
detriment
inhibitori
activ
also
presenc
ortho
substitu
aromat
ring
benzyl
group
especi
trifluoromethyl
group
enhanc
inhibitori
activ
final
prachayasittikul
cowork
found
triazol
deriv
sulfonamid
analogu
potent
aromatas
inhibitori
activ
compound
fig
bear
substitu
isoquinolin
ring
show
potent
aromatas
inhibitori
activ
ic
mm
without
affect
normal
cell
sar
suggest
lipophil
effect
dimethoxi
group
enhanc
activ
compound
addit
molecular
dock
studi
perform
activ
compound
mode
bind
interact
compound
reveal
investig
triazol
could
close
engag
activ
site
aromatas
interact
hydrophob
pp
stack
hbond
furthermor
hydrophob
interact
observ
protein
interact
fig
compound
arrang
way
appropri
form
hydrogen
bond
sulfonyl
group
amino
group
well
hydrogen
bond
oxycoumarinyl
moieti
hydrophob
hydrogen
bond
interact
suggest
play
pertin
role
contribut
potent
activ
compound
interestingli
isomer
coumarinyl
naphthalenyl
triazol
play
crucial
role
exert
potent
aromatas
inhibitori
activ
test
compound
could
attribut
bind
interact
aromatas
enzym
molecular
requir
potent
triazol
inhibitor
contain
group
posit
triazol
ring
msubstitut
triazol
sulfonyl
moieti
phenyl
ring
structur
featur
essenti
engag
hydrophob
pp
stack
hbond
interact
aromatas
enzym
particularli
hydrogen
bond
form
review
updat
summari
import
sulfonyl
sulfonamid
base
scaffold
vi
base
moieti
bioactiv
compound
describ
sulfonamid
base
hybrid
huge
rang
biolog
activ
antimicrobi
antidiabet
antiinflammatori
antimalari
antitubercular
antivir
alzheim
activ
anticonvuls
anticanc
antitubercular
activ
theoret
sulfonyl
sulphonamid
vi
moieti
base
drug
possess
immens
potenti
therapeut
valu
divers
drug
target
sar
base
work
probabl
continu
play
import
role
optim
full
potenti
sulfonamid
hybrid
mani
potenti
drug
yet
clinic
trial
emphas
exig
need
derivat
provid
opportun
manag
therapeut
valu
effici
greater
efficaci
futur
addit
biolog
agent
promis
activ
welldefin
mechan
action
consid
valuabl
candid
prototyp
design
develop
novel
effect
synthet
compound
base
potent
inhibitor
